Ambrx Snags $2 Billion Takeover, But CEO Dan O'Connor Says Don't Call It 'Hot'
Cancer-focused biotech companies Ambrx and Harpoon snapped up a pair of takeover deals. AMAM stock and HARP stock soared.
Skip to navigation Skip to main content Skip to right column 
Ambrx Snags $2 Billion Takeover, But CEO Dan O'Connor Says Don't Call It 'Hot' · Investor's Business Daily